Shares in Oxford Nanopore Technologies (LSE:ONT) rose about 3.4% on 22 September to close at 178p, picking up a September rally that had paused the previous day. No new company announcement explained the move. The DNA and RNA sequencing specialist has gained around 15% since mid-September and has recovered strongly from July's low, helped by a well-received set of interim results and a European Patent win against a Chinese rival.

What happened

Oxford Nanopore closed up 5.8p, or about 3.37%, at 178p on Tuesday, against a previous close of 172.2p. Earlier reports during the session put the gain at around 2.8%. The move reversed a small dip on Monday, when the shares slipped from 174.4p, and followed four straight daily gains from 15 to 18 September.

Oxford Nanopore's most recent regulatory announcements do not include anything issued on 22 September. However, the company had said earlier this month that chief financial officer Nick Keher would take part in a fireside chat at a virtual investor conference for life-science tools companies that day. Chief executive Francis Van Parys and Mr Keher had also appeared at a healthcare investor conference in New York on 15 September. There is no evidence that anything new was disclosed at either event, but investor meetings often keep a stock in focus.

The more concrete recent news came on 16 September. Oxford Nanopore said the Munich Local Division of the Unified Patent Court had granted a preliminary injunction against MGI Tech GmbH over its CycloneSEQ nanopore sequencing systems. The order stops MGI Tech from making, selling, importing or using those systems and related flow cells in several European countries, including Germany, France, the Netherlands and the UK, pending a full trial scheduled for October 2027. The shares rose on that day and more sharply the next.

What the numbers show

Interim results published on 19 August showed Revenue up 10.5% to £116.7m for the six months to 30 June, or 12.3% at constant currency. Gross Margin rose 400 basis points to 62.2%, helped by better flow-cell yields, scale and a new pricing model. The adjusted EBITDA loss more than halved to £22.1m from £48.3m, and the statutory loss narrowed to £48.0m from £71.8m.

Growth was strongest in the applied markets. Clinical revenue rose 35.4% and biopharma revenue 25.0%, while industrial grew 6.2% and academic 5.4%. By region, Europe, the Middle East, India and Africa rose 23.8% at constant currency and the Americas 12.5%, but Asia-Pacific fell 8.4% as revenue in China dropped 15.7%.

Guidance was broadly maintained. Excluding $20m of one-off revenue from a new global cross-licensing agreement, Oxford Nanopore still expects constant-currency revenue growth of 16–20% in 2026, and roughly 23–27% including it. It cut its forecast for operating-cost growth to between minus 2% and zero, reaffirmed its targets of adjusted EBITDA breakeven in 2027 and positive free Cash Flow in 2028, and set a new goal of revenue above $700m by 2030. Van Parys said the group was "tracking well towards adjusted EBITDA breakeven in FY27".

The share-price recovery has been substantial. The shares hit a 52-week low of 95.7p on 13 July, when a half-year trading update disappointed, and a high of 191.4p on 27 August. The stock closed at 122.2p the day before the interims and rose about 14% on results day, followed by a further gain of around 18% the day after. It has risen about 55% over three months, giving a Market Value of roughly £1.74bn.

Why it matters

Oxford Nanopore, a University of Oxford spin-out and FTSE 250 constituent, makes sequencing devices ranging from the pocket-sized MinION to the high-throughput PromethION. They read DNA and RNA by passing strands through nanoscale pores, and the approach offers long reads, real-time data and portability, which set it apart from short-read rivals. The PromethION range grew 15.7% in the first half, helped by Demand for the P2i instrument.

The Investment case rests on moving from a laboratory-tools supplier to a Business with steady clinical and biopharma revenue, and on getting there without needing fresh funding. With £234.5m of cash and liquid investments at 30 June and cost growth now expected to be flat or slightly negative, the market appears more willing to believe the breakeven target is credible.

The patent ruling also matters strategically. It confirms Oxford Nanopore's willingness to defend its intellectual property in Europe as competitors bring rival nanopore-based platforms to market.

Risks to consider

The company remains loss-making, and the path to breakeven depends on growth accelerating in the second half. The July trading update showed how quickly sentiment can turn: first-half trading came in below management's expectations, mainly because of export-control restrictions and operational changes in China and disruption in the Middle East.

Academic customers, still the largest end market, face continued funding pressures, which the company flagged in the Americas. Cash fell by about £68m in the first half, partly because of seasonal working-capital outflows and Bonus payments, so investors will want to see the promised improvement in second-half cash conversion.

The MGI injunction is preliminary, can be appealed and will be tested again at trial. After a rise of more than 50% in three months, the shares may also be sensitive to profit-taking or a wider sell-off in growth stocks.

What to watch next

No further results dates had been confirmed at the time of writing. For reference, Oxford Nanopore issued its half-year trading update in mid-July and its final results for 2025 in early March 2026. In the meantime, investors will watch for commercial updates in clinical and biopharma, any appeal by MGI, and signs that trading in China has stabilised.

Conclusion

For Oxford Nanopore (LSE:ONT), Tuesday's gain of around 3.4% had no fresh announcement behind it, but it fits a clear trend. Since July's low, Oxford Nanopore has benefited from a sharp improvement in margins, reaffirmed breakeven targets, a leaner cost outlook and a significant patent win in Europe. The rally has been rapid, and much now depends on whether the second half delivers the stronger revenue and cash flow that management has promised.